Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Standard
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. / Hübel, K; Fresen, M M; Salwender, H; Basara, N; Beier, R; Theurich, S; Christopeit, M; Bogner, C; Galm, O; Hartwig, R; Heits, F; Lordick, F; Rösler, W; Wehler, D; Zander, Axel R.; Albert, M H; Dressler, S; Ebinger, M; Frickhofen, N; Hertenstein, B; Kiehl, M; Liebler, S; von Lilienfeld-Toal, M; Weidmann, E; Weigelt, C; Lange, F; Kröger, Nicolaus.
in: BONE MARROW TRANSPL, Jahrgang 46, Nr. 8, 8, 2011, S. 1045-1052.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
AU - Hübel, K
AU - Fresen, M M
AU - Salwender, H
AU - Basara, N
AU - Beier, R
AU - Theurich, S
AU - Christopeit, M
AU - Bogner, C
AU - Galm, O
AU - Hartwig, R
AU - Heits, F
AU - Lordick, F
AU - Rösler, W
AU - Wehler, D
AU - Zander, Axel R.
AU - Albert, M H
AU - Dressler, S
AU - Ebinger, M
AU - Frickhofen, N
AU - Hertenstein, B
AU - Kiehl, M
AU - Liebler, S
AU - von Lilienfeld-Toal, M
AU - Weidmann, E
AU - Weigelt, C
AU - Lange, F
AU - Kröger, Nicolaus
PY - 2011
Y1 - 2011
N2 - The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 g/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/ L. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 10(6) CD34+ cells/kg (1.6-5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 10(6) CD34+ cells/kg (0-24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.Bone Marrow Transplantation advance online publication, 25 October 2010; doi:10.1038/bmt.2010.249.
AB - The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 g/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/ L. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 10(6) CD34+ cells/kg (1.6-5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 10(6) CD34+ cells/kg (0-24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.Bone Marrow Transplantation advance online publication, 25 October 2010; doi:10.1038/bmt.2010.249.
M3 - SCORING: Zeitschriftenaufsatz
VL - 46
SP - 1045
EP - 1052
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 8
M1 - 8
ER -